Jeff Davis, a partner in the Washington, D.C., law office of Bass, Berry & Sims, advises healthcare organizations on Medicare and Medicaid billing and reimbursement issues, with a special focus on the ...

Four drug manufacturers have announced plans to offer discounted drug prices to safety net providers under the federal 340B program via rebates instead of upfront discounts, despite the federal ...

On July 31, 2025, the Health Resources and Services Administration (HRSA), Office of Pharmacy Affairs (OPA) issued a 340B Drug Pricing Program notice (the “Notice”) announcing the launch of a ...

Johnson & Johnson is backing down from using its planned rebate model in the 340B program. In a September 30 letter to the Health Resource and Services Administration, J&J said it would not implement ...

While a federal judge squashed earlier plans for a 340B rebate pilot program, HHS appears poised to relaunch its attempts to transform the drug pricing program. Less than two weeks after the federal ...

Sanofi is joining its fellow drugmakers in trying to put new restrictions on savings sent to hospitals in a federal drug discount program. A spokesperson for Sanofi confirmed plans to implement a ...

The Health Resources and Services Administration has opened applications for a voluntary pilot program aimed at evaluating the 340B rebate model. The 340B Program traditionally has offered up-front ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

More than 90% of employers agreed a rebate-free approach is easier to understand and would improve drug price transparency, ...